Amedisys (NASDAQ:AMED) Rating Increased to Buy at StockNews.com

Amedisys (NASDAQ:AMED) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other equities analysts also recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a research report on Thursday, April 25th. Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Finally, Royal Bank of Canada boosted their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $100.80.

Amedisys Trading Down 0.4 %

AMED stock opened at $92.08 on Friday. The firm’s fifty day simple moving average is $92.36 and its two-hundred day simple moving average is $93.32. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -143.87, a price-to-earnings-growth ratio of 3.43 and a beta of 0.84. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31. Amedisys has a twelve month low of $73.10 and a twelve month high of $96.44.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The company had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. During the same period in the prior year, the company posted $1.00 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, analysts anticipate that Amedisys will post 4.57 earnings per share for the current year.

Hedge Funds Weigh In On Amedisys

A number of large investors have recently bought and sold shares of AMED. Banque Cantonale Vaudoise purchased a new position in shares of Amedisys in the 1st quarter valued at $60,000. Cetera Trust Company N.A purchased a new position in Amedisys in the fourth quarter valued at about $215,000. CWM LLC raised its holdings in Amedisys by 40.4% in the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in shares of Amedisys during the fourth quarter valued at about $258,000. Finally, Mesirow Institutional Investment Management Inc. boosted its holdings in shares of Amedisys by 9.9% in the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock valued at $270,000 after buying an additional 257 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.